Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;139(6):1119-1122.
doi: 10.1007/s00401-020-02147-5. Epub 2020 Mar 10.

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis

Sarah Hoffmann  1 , Lutz Harms  2 , Markus Schuelke  3 , Jens-Carsten Rückert  4 , Hans-Hilmar Goebel  5   6 , Werner Stenzel #  5 , Andreas Meisel #  2
Affiliations

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis

Sarah Hoffmann et al. Acta Neuropathol. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Sarah Hoffmann has received speaker honoraria from Alexion. Lutz Harms received honoraria from Alexion for speaking and consulting services. Markus Schuelke has no conflicts of interest. Jens-Carsten Rückert has no conflicts of interest. Hans-Hilmar Goebel has no conflicts of interest. Werner Stenzel has no conflicts of interest. Andreas Meisel received speaker honoraria from Alexion, GRIFOLS and Hormosan. He received honoraria from Alexion, MorphoSys and Vitaccess for consulting services and financial research support from Octapharma and Alexion. Andreas Meisel is chairman of the medical advisory board of the German Myasthenia Gravis Society (Deutsche Myasthenie Gesellschaft, DMG).

Figures

Fig. 1
Fig. 1
Representative findings in a SNMG patient’s muscle showing a an endplate area stained by Gömöri trichrome with fibres standing apart from each other and sometimes small nerve fascicles penetrating, b endplates stained for non-specific esterase (NSE, enzyme histochemical staining), endplates positive for c C5b-9 (immunehistochemical staining), and d C1q (immunofluorescence staining, AF488-direct labelling; green), e endplates co-stained for C5b-9 (immunofluorescence staining, AF488; green) and IgG1 (Cy3; red), nuclei are stained with DAPI (blue) f no major plump or shortened postsynaptic clefts by electron microscopy (original magnification of × 20.000; all other stains with original magnification of  × 400). Representative findings in an AChR-ab-positive MG patient’s muscle showing g an endplate area stained by Gömöri trichrome, h endplates stained for NSE endplates, endplates positive for i C5b-9 and j C1q (AF488; green), k endplates, co-stained for C5b-9 (green) and IgG1 (red), nuclei (blue) l no major plump or shortened postsynaptic clefts by electron microscopy (original magnification of × 20.000; all other stains with original magnification of × 400). Representative findings of a non-disease control showing m an endplate area stained by Gömöri trichrome, n endplates stained for NSE o endplates without positivity for C5b-9, the endplate area can be clearly identified by the presence of terminal nerve endings. All stains with original magnification of × 400. SNMG seronegative myasthenia gravis, AchR + MG acetylcholine receptor antibody-positive myasthenia gravis, NDC non-diseased controls
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267–280. - PubMed
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. doi: 10.1016/S1474-4422(15)00145-3. - DOI - PubMed
    1. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–422. doi: 10.1002/ana.22312. - DOI - PubMed
    1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–368. doi: 10.1038/85520. - DOI - PubMed
    1. Howard JF, Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–986. doi: 10.1016/S1474-4422(17)30369-1. - DOI - PubMed

Publication types